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Abstract
Background: Family history is among the few established risk factors for testicular germ cell tumor (TGCT).
Approximately 1.4% of newly diagnosed TGCT patients report a positive family history of TGCT. Sons and siblings of
TGCT patients have four- to six fold and eight- to tenfold increase in TGCT risk, respectively. In twins of men with
TGCT the relative risk of testicular cancer is 37.5 (12.3-115.6). Nevertheless, information about the occurrence of
TGCT in relatives of patients with extragonadal germ cell tumor is limited.
Case report: A 24 year-old male patient was diagnosed with a mediastinum tumor and was submitted to image-
guided biopsy, which revealed a seminoma. Two months later, his non-identical asymptomatic twin brother was
submitted to an elective ultrasound of the testes, which showed a left testicular mass of 4.2 cm. This patient
underwent orchiectomy revealing a seminoma of the left testis. There are no other cases of seminoma or other
types of cancers reported in first-degree relatives in this family.
Conclusions: Although familial aggregations of TGCT have been well described, to the best of our knowledge, no
data concerning the association of gonadal and extragonadal germ cell tumor in relatives has been previously
reported. Further investigation on this association is warranted and may help in improving our knowledge of
familial pattern inheritance.
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Background
Testicular germ cell tumor (TGCT) is the most common
malignancy in males aging 15–35. Known risk factors
for TGCT include: cryptorchidism, testicular dysgenesis,
infertility, testicular microlithiasis, previously diagnosed
TGCT and a family history of the disease [1].
Familial aggregations of TGCT have been well de-
scribed, suggesting the existence of a hereditary TGCT
subset. Approximately 1.4% of newly diagnosed TGCT
patients report a positive family history of TGCT [2].
Epidemiological studies have shown that there is an
eight to ten fold increase in relative risk of TGCT for
brothers of patients and a fourfold increased risk for
fathers and sons [3,4]. Moreover, testicular cancer risk
was raised in twins of men with testicular cancer (rela-
tive risk = 37.5 [12.3-115.6]); risk was greater but not
significantly in monozygotic than in dizygotic twins
(p = 0.45). The cumulative risk of testicular cancer by the
age of 40 years in men whose monozygotic twins had tes-
ticular cancer was 14% (4–46) [5]. A previous study using
segregation analysis of testicular cancer favored an auto-
somal recessive model of inheritance [6] and, although no
high-penetrance cancer susceptibility gene has been mapped
yet, linkage analyses have identified several genomic regions
of modest interest [7]. Y chromosome gr/gr deletion and
PDE11A gene mutations have been suggested to modify the
risk of familial testicular germ cell tumor (FTGCT) [8,9].
Phenotypic aspects of FTGCT include 2 cases of TGCT
per family, mean age at diagnosis about 2.5 years
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younger than that observed for sporadic TGCT and
greater prevalence of bilateral cancer [10].
The establishment of a universal screening program
using testicular palpation (clinical or patient self-
examination) or serum biomarker for healthy young pa-
tients lacks clinical evidence [11]. And, although some
risk factors for TGCT are well known, effectiveness of
high-risk patients screening is controversial. Recent sys-
tematic review did not detect published randomized
clinical trials comparing screening versus no screening
for testicular cancer [12]. On the basis of uncertain ben-
efits and some likelihood of harms, the US Preventive
Services Task Force and the American Academy of Fam-
ily Physicians discourage screening. But others, such as
the American Cancer Society and the European Associ-
ation of Urology, recommend different approaches: tes-
ticular examination to be part of a periodic cancer-
related checkup [13] and self-testicular examination for
individuals with clinical risk factors [14], respectively.
Extragonadal germ cell tumors account for fewer than
10% of all germ cell malignancies. All reports of family in-
heritance focused exclusively in isolated germ cell tumors
of testis [4,6,7] and the estimation of the contribution of
extragonadal germ cell tumor in the familial setting is not
known. Therefore, the omission of extragonadal tumors in
the published reports may have contributed to the under-
estimation of the importance of the hereditary factor of
germ cell tumors, especially when there is a presence of
an affected twin. Here we present a report of simultaneous
occurrence of seminomas in dizygotic twins: one in the
testicle and the other in the mediastinum.
Case report
A 24 year-old male patient was first diagnosed with a
mediastinal mass. Other lesions were not found else-
where in the body, including the testicles. A computed
tomography-guided transthoracic biopsy led to the diag-
nosis of primary mediastinal seminoma. Two months
after, his non-identical asymptomatic twin brother was
then submitted to an elective ultrasound of the testes,
which showed a left testicular mass of 4.2 cm. After ex-
cluding extragonadal disease, this patient underwent or-
chiectomy that revealed a pure seminoma of the left
testis with rete testis invasion. There are no other cases
of seminoma or other types of cancers reported in first-
degree relatives of this family. Initially, the first patient
received 4 cycles of bleomycin, cisplatin, and etoposide
(BEP) and is now following a residual mediastinal mass
with serial images. His brother has no evidence of dis-
ease after 1 cycle of carboplatin AUC 7 mg/mL.
Discussion
Although mediastinal germ cell neoplasms account for
only 2% to 5% of all germinal tumors, they constitute up
to 50% to 70% of all extragonadal tumors. When this
mediastinal tumor is identified, it is mandatory to ex-
clude TGCT. Daugaard et al. reported that, while carcin-
oma in situ testis (CIST) was diagnosed in 42% of germ
cell primary tumors of retroperitoneum, indicating that
these tumors are probably not truly extragonadal, none
of the patients with tumors in mediastinum who under-
went biopsy had CIST [15]. Accordingly, the vast major-
ity of patients with mediastinal tumor will not develop
testicular tumors and, as a consequence, will not be ana-
lyzed in epidemiological studies using population data-
bases. In this sense, although the familial association of
gonadal and extragonadal germ cell tumors has not yet
been established, based on the present case report it is
possible to question if the exclusion of extragonadal
germ cell tumors from FTGCT studies may exert a
negative influence on the advances of the knowledge re-
garding the underlying common genetic mechanisms of
germ cell tumors.
Furthermore, it is important to note that the decision
of performing the investigation on the asymptomatic
brother was closely guided by the information provided
in previous studies of FTGCT [1]. This initiative permit-
ted an early tumor diagnosis and, consequently, greater
chances of successful treatment without an unnecessary
exposure to the acute and late toxicities of BEP. In this
perspective, we would like to propose the discussion of
whether we should start including extragonadal germ
cell tumors in studies of families with testicular germ
cell tumors.
Nevertheless, further investigations in other clinical
and population based studies are necessary and may im-
prove our understanding of familial pattern of inheri-
tance. We believe that future research on the association
of testicular and extragonadal germ cell tumors in the
familial setting may provide new insights and discoveries
in the field and, hopefully, help on the design of stra-
tegies for prevention, screening and follow-up of families
with germ cell tumors, especially when there is a pres-
ence of an affected twin.
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